SEC Form 4

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| 1. Name and Address of Reporting Person* LYONS GARY A | | Person* | 2. Issuer Name and Ticker or Trading Symbol <u>NEUROCRINE BIOSCIENCES INC</u> [NBIX | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|--|-------------|----------|---|--|-----------------------------------|-----------------------|--|--|--|
| LIONS GAI | <u>XI A</u> | | 1 | X | Director | 10% Owner | | | |
| (Last) | (First) | (Middle) | | x | Officer (give title below) | Other (specify below) | | | |
| NEUROCRINE BIOSCIENCES, INC. | | () | 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2007 | President and CEO | | | | | |
| 12790 EL CAM | INO REAL | | | | | | | | |
| (Street) | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indi Line) | vidual or Joint/Group Filir | ng (Check Applicable | | | |
| SAN DIEGO | СА | 92130 | | X | Form filed by One Rep | porting Person | | | |
| | | 52150 | | | Form filed by More that Person | an One Reporting | | | |
| (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | |
|---------------------------------|--|---|-----------------------------|---|---|---------------|-------|---|---|---|--|--|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and | ed nstr. | 6. Date Exerc Expiration Da (Month/Day/M | ate | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|---|-------------|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option ⁽¹⁾ | \$10.98 | 03/16/2007 | | A | | 85,000 | | 03/16/2008 | 03/16/2014 | Common Stock | 85,000 | \$10.98 | 85,000 | D | |
| Restricted Stock Unit | (2) | 03/16/2007 | | A | | 85,000 | | (3) | (3) | Common Stock | 85,000 | \$ <mark>0</mark> | 85,000 | D | |

Explanation of Responses:

1. Represents option of which 1/3 of the shares underlying the option becomes vested and exercisable on March 16, 2008, March 16, 2009 and March 16, 2010, respectively.

2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.

3. The restricted stock units will vest at 1/2 of the units vesting on the date Neurocrine receives FDA approval of an indiplon NDA and 1/2 of the units vesting on the first commercial sale of indiplon by Neurocrine

Remarks:

Margaret E. Valeur-Jensen, By Power of Attorney

** Signature of Reporting Person Date

03/20/2007

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.